Randomized Controlled Trial of a Drug Regimen That Includes Ciproftoxacin for the Treatment of Pulmonary Tuberculosis

Authors:
  • LBL. Berger
    L. Berger
  • JCJ. Curram
    J. Curram
  • RFR. Fox
    R. Fox
  • JGJ. Gutmann
    J. Gutmann
  • GKG. M. Kisyombe
    G. M. Kisyombe
  • FNF. I. Ngowi
    F. I. Ngowi
  • ARA. R. C. Ramsay
    A. R. C. Ramsay
  • ASA. O. S. Saruni
    A. O. S. Saruni
  • NSN. Sam
    N. Sam
  • GTG. Tillotson
    G. Tillotson
  • LUL. O. Uiso
    L. O. Uiso
Open Access
Publisher website
Google Scholar
Abstract
The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 rng), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV-infected patients.